Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Cost of Quality (COQ)  -  Worth Every Cent in Pharmaceutical Manufacturing

QxP founder Crystal Mersh makes her views “Crystal Clear” in her recent Pharmaceutical Online article: ”Cost of Quality (COQ) - Worth Every Cent in Pharmaceutical Manufacturing.”  

This excerpt gives you a sense of what to expect when you read it: 

“During my career as an executive in pharmaceutical manufacturing quality assurance, I have heard the term ‘Cost of Quality,’ or ‘COQ’ for short, over and over when advocating for budget and resources. In many cases, management has viewed budget items for improving systems, equipment, learner education, and qualifying secondary suppliers and their materials, as ‘nice to haves’ instead of necessities. As a result, these quality system areas were not invested in as much as is necessary to ensure optimal bottom-line results.  

Decisions not to invest adequately in these and other important quality areas often do not take into consideration the realities of the risk and likelihood of failure, which lead to a higher Cost of Poor Quality (COPQ). In effect, these decisions allow for providing poor quality products and services and increasing the risk of financial loss and reputational damage. The COPQ must be built into the equation to determine COQ, and when it is, you will see that the Cost of Poor Quality is too high for any pharmaceutical manufacturer to endure.” 

Yes, it is worth a close read. Here is the link:

The bottom line is this: When your company is assessing the cost of quality, make sure it considers the entire equation: COQ = PC+AC +IFC +EFC.  

PC:  Prevention Costs 

AC:  Appraisal Costs 

IFC: Internal Failure Costs 

EFC: External Failure Costs 

Quality Executive Partners has engaged in partnering with industry over the 10 years. During our engagements with you, we have developed many case studies proving that the COQ is so worth it. When you sit down and think about this equation more, you will find that the cost of quality is worth every penny and the COPQ is too much for your company to endure. 


QxP Founder and CEO Crystal Mersh’s career in pharma quality has spanned three decades and huge companies. Prior to founding QxP in 2012, Crystal has worked in leadership roles at Mylan, Novartis, Watson Pharmaceuticals, and Sanofi. 

Click here to read Crystal’s article about why “Controls Are Not Enough.”

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls are not enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023